The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes and molecular correlates of incorporating immunotherapy (IO) and bevacizumab (Bev) in treating patients with peritoneal mesothelioma (PeM): A comparative analysis with pleural mesothelioma (PM).
 
Ryan W. Huey
Honoraria - Aptitude Health; Clinical Care Targeted Communications LLC; Vizient
Travel, Accommodations, Expenses - Clinical Care Targeted Communications LLC; Vizient
 
Nishant Gandhi
Employment - Caris Life Sciences
 
Beth A. Helmink
No Relationships to Disclose
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Roche/Genentech; Simcere
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Anais Malpica
No Relationships to Disclose
 
Jeannelyn Estrella
No Relationships to Disclose
 
Melissa Taggart
No Relationships to Disclose
 
Joelle Allam
No Relationships to Disclose
 
Christopher Scally
No Relationships to Disclose
 
Paul F. Mansfield
Stock and Other Ownership Interests - Amgen; LabCorp; Stryker
Patents, Royalties, Other Intellectual Property - Royalties for up to date
 
Aurelio Matamoros
No Relationships to Disclose
 
Andrew Elliott
Employment - Caris Life Sciences
 
Ari VanderWalde
Employment - Caris Life Sciences
 
Patrick C. Ma
Honoraria - AstraZeneca; BeiGene
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Elevation Oncology (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); OncoC4 (Inst); Roche/Genentech (Inst)
 
Balazs Halmos
Consulting or Advisory Role - Apollomics; Arcus Biosciences; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Genentech/Roche; Janssen Oncology; Lilly; Merck; merus; Novartis; Pfizer; Takeda; Turning Point Therapeutics; Veracyte
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen; AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Forward (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Takeda (Inst); Tesaro/GSK (Inst)
 
Stephen V Liu
No Relationships to Disclose
 
Keith F. Fournier
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)